An editorial review of the kisspeptin literature — the KISS1R neuropeptide that sits upstream of the whole reproductive axis, and what the human trials actually found.
Kisspeptin Reviews

Doses studied

Kisspeptin dosage in the research record: by population, by route, never as advice

What was administered, to whom, and how — plus the half-life and the desensitization that make schedule the whole game.

Read this first

There is no recommended human dose of kisspeptin, and this page does not provide one. Every number here is a research protocol — what investigators gave to a specific study population, by a specific route, reported as "studied at X in [population] by [route]." Kisspeptin is investigational, so this is description, not instruction.

Two facts shape everything about kisspeptin dosage. First, the two isoforms behave very differently in time: kisspeptin-10 clears in minutes, kisspeptin-54 lasts far longer. Second, and more important, continuous or high-dose exposure desensitizes the receptor within days — tachyphylaxis — so giving more, or giving it constantly, does not reliably produce more effect and can produce less [4][16]. Real research protocols are built around that limit, favoring single boluses or well-spaced exposure over continuous drips. The numbers below are organized by what was actually tested.

Kisspeptin dosage by population and route

Across the human literature, kisspeptin has been studied at: an intravenous bolus of 0.3 to 1.0 ug/kg in healthy men, with continuous infusion at 1.5 ug/kg/h [3]; a continuous intravenous infusion of 0.01 to 1.00 nmol/kg/h in women with hypothalamic amenorrhea [4]; and a subcutaneous bolus of 3.2 to 12.8 nmol/kg as an IVF oocyte-maturation trigger, with the optimal live-birth result near 9.6 nmol/kg [5]. Bone and mood studies used roughly 1 nmol/kg/h by infusion [11].

Every one of those is a supervised research dose in a defined population, not a protocol for self-administration. The doses are not interchangeable between isoforms or routes, and the responses are measured by hormone labs and clinical outcomes, not by subjective feel.

Kisspeptin nasal spray: the non-invasive route

A kisspeptin nasal spray is the newest delivery route in the literature. In a 2025 study, intranasal kisspeptin-54 (primary dose 12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L), with no reported adverse events [6]. The nasal-spray formulation was stable for up to 60 days at 4 degrees C [6].

This is significant because every earlier reproductive protocol required injection or infusion. A working non-invasive route lowers the practical barrier for future research — but it remains a research finding in a controlled study, not an approved or self-administered product.

Kisspeptin half life and stability

The kisspeptin half life differs sharply by isoform, and it explains much of the dosing behavior. Kisspeptin-10 has a functional half-life of approximately 4 minutes in humans, cleared rapidly by plasma peptidases (enzymes that chop up peptides) [3]. Kisspeptin-54 lasts far longer — approximately 27 to 28 minutes — because its larger size and greater resistance to enzymatic cleavage slow its breakdown [4].

That short half-life is not only a limitation; it can be an advantage. Because kisspeptin-10 clears so quickly, receptor sensitivity may be better preserved with well-spaced or pulsatile exposure than with a continuous drip, which drives the tachyphylaxis described above [4][16]. On stability, the 2025 intranasal kisspeptin-54 formulation held up for 60 days refrigerated; research-grade lyophilized peptide is otherwise typically kept cold [6].